CN102548574B - Npr-b激动剂 - Google Patents

Npr-b激动剂 Download PDF

Info

Publication number
CN102548574B
CN102548574B CN201080042799.0A CN201080042799A CN102548574B CN 102548574 B CN102548574 B CN 102548574B CN 201080042799 A CN201080042799 A CN 201080042799A CN 102548574 B CN102548574 B CN 102548574B
Authority
CN
China
Prior art keywords
leu
seqidno
arg
nml
occ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080042799.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102548574A (zh
Inventor
F·奥斯特坎普
H·哈姆里施
G·胡梅尔
T·克瑙特
U·赖默
U·赖尼克
U·里希特
B·西蒙
E·斯佩克
M·沃伊施尼克
M·R·赫尔博格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Shire Orphan Therapies GmbH
Alcon Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102548574(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Orphan Therapies GmbH, Alcon Research LLC filed Critical Shire Orphan Therapies GmbH
Publication of CN102548574A publication Critical patent/CN102548574A/zh
Application granted granted Critical
Publication of CN102548574B publication Critical patent/CN102548574B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080042799.0A 2009-09-25 2010-09-23 Npr-b激动剂 Expired - Fee Related CN102548574B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
US61/245,960 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610116122.6A Division CN105732767A (zh) 2009-09-25 2010-09-23 新的npr-b激动剂

Publications (2)

Publication Number Publication Date
CN102548574A CN102548574A (zh) 2012-07-04
CN102548574B true CN102548574B (zh) 2016-03-23

Family

ID=43781057

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080042799.0A Expired - Fee Related CN102548574B (zh) 2009-09-25 2010-09-23 Npr-b激动剂
CN201610116122.6A Pending CN105732767A (zh) 2009-09-25 2010-09-23 新的npr-b激动剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610116122.6A Pending CN105732767A (zh) 2009-09-25 2010-09-23 新的npr-b激动剂

Country Status (17)

Country Link
US (5) US8546523B2 (enExample)
EP (1) EP2480247B1 (enExample)
JP (3) JP5893561B2 (enExample)
KR (3) KR20180049198A (enExample)
CN (2) CN102548574B (enExample)
AR (1) AR078445A1 (enExample)
AU (1) AU2010298256B2 (enExample)
BR (1) BR112012006579A2 (enExample)
CA (1) CA2773949C (enExample)
CL (2) CL2012000715A1 (enExample)
MX (3) MX2012003398A (enExample)
PH (1) PH12012500562A1 (enExample)
RU (3) RU2636738C2 (enExample)
TW (2) TWI577384B (enExample)
UY (1) UY32902A (enExample)
WO (1) WO2011038061A2 (enExample)
ZA (3) ZA201201630B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732406B2 (en) 2005-04-07 2010-06-08 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
PH12012500562A1 (en) 2009-09-25 2012-10-22 Takeda Pharmaceuticals Co Novel npr-b antagonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
CA2853204A1 (en) * 2011-12-16 2013-06-20 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
NZ710246A (en) * 2013-01-25 2016-11-25 Cardiorentis Ltd Methods of treating cardiovasular indications
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
EP3576770A1 (en) * 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
CA3056433A1 (en) 2017-03-22 2018-09-27 Pharmain Corporation Npra agonists, compositions, and uses thereof
US20210121534A1 (en) * 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
EP3880685B1 (en) * 2018-11-16 2025-06-18 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
US20230416328A1 (en) * 2020-06-12 2023-12-28 Hirofumi Tachibana C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196754A1 (en) * 2000-03-31 2005-09-08 Drmanac Radoje T. Novel nucleic acids and polypeptides
WO2007047504A2 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
US20080153747A1 (en) * 2004-07-15 2008-06-26 The University Of Queensland Proteinaceous compounds and uses therefor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
EP0323740A3 (en) * 1987-12-24 1990-12-12 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
JP2848411B2 (ja) * 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
EP1118329A4 (en) 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2007034498A1 (en) * 2005-09-26 2007-03-29 Compugen Ltd. Atrial natriuretic peptide (anp) splice variants and methods of using same
AU2007233116B2 (en) * 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
PH12012500562A1 (en) 2009-09-25 2012-10-22 Takeda Pharmaceuticals Co Novel npr-b antagonists
US8551938B2 (en) 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196754A1 (en) * 2000-03-31 2005-09-08 Drmanac Radoje T. Novel nucleic acids and polypeptides
US20080153747A1 (en) * 2004-07-15 2008-06-26 The University Of Queensland Proteinaceous compounds and uses therefor
WO2007047504A2 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins

Also Published As

Publication number Publication date
EP2480247A2 (en) 2012-08-01
US20160194357A1 (en) 2016-07-07
KR101768661B1 (ko) 2017-08-16
TWI577384B (zh) 2017-04-11
UY32902A (es) 2011-02-28
EP2480247A4 (en) 2013-09-04
AU2010298256A1 (en) 2012-04-12
ZA201702958B (en) 2018-08-29
WO2011038061A2 (en) 2011-03-31
JP2017137362A (ja) 2017-08-10
KR20180049198A (ko) 2018-05-10
US20110077381A1 (en) 2011-03-31
MX2012003398A (es) 2012-04-10
US20170313743A1 (en) 2017-11-02
JP6211032B2 (ja) 2017-10-11
US20180334477A1 (en) 2018-11-22
RU2012116531A (ru) 2013-10-27
AU2010298256B2 (en) 2015-08-13
CA2773949A1 (en) 2011-03-31
RU2015124607A (ru) 2015-12-10
CA2773949C (en) 2020-11-03
KR101854820B1 (ko) 2018-05-04
KR20170094564A (ko) 2017-08-18
CL2017001190A1 (es) 2017-12-01
US9169293B2 (en) 2015-10-27
CL2012000715A1 (es) 2012-11-30
TWI625126B (zh) 2018-06-01
BR112012006579A2 (pt) 2016-11-22
RU2017139870A3 (enExample) 2019-05-16
MX354005B (es) 2018-02-08
ZA201201630B (en) 2014-05-28
RU2557290C2 (ru) 2015-07-20
US8546523B2 (en) 2013-10-01
US20130345394A1 (en) 2013-12-26
KR20120091110A (ko) 2012-08-17
EP2480247B1 (en) 2020-02-12
PH12012500562A1 (en) 2012-10-22
AR078445A1 (es) 2011-11-09
CN105732767A (zh) 2016-07-06
WO2011038061A3 (en) 2011-07-28
US9745344B2 (en) 2017-08-29
ZA201401625B (en) 2018-08-25
MX370645B (es) 2019-12-19
JP2013505937A (ja) 2013-02-21
US10196423B2 (en) 2019-02-05
JP5893561B2 (ja) 2016-03-23
JP2015131856A (ja) 2015-07-23
RU2017139870A (ru) 2019-05-16
RU2636738C2 (ru) 2017-11-28
CN102548574A (zh) 2012-07-04
US9982016B2 (en) 2018-05-29
TW201110974A (en) 2011-04-01
TW201630619A (zh) 2016-09-01

Similar Documents

Publication Publication Date Title
JP6211032B2 (ja) 新規ｎｐｒ−ｂアゴニスト
US8551938B2 (en) NPR-B agonists
WO2011075471A2 (en) Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
US20180094029A1 (en) Methods of treating ophthalmic diseases using npr-b agonists
US9458198B1 (en) Cyclic peptide-based NPR-B agonists
AU2015255299B2 (en) Novel npr-b agonists
HK1226800A (en) Novel npr-b agonists
HK1226800A1 (en) Novel npr-b agonists
HK1173070A (en) Novel npr-b agonists
HK1173070B (en) Novel npr-b agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: FUER ORPHAN TREATMENT CO., LTD.

Free format text: FORMER OWNER: ALCON MFG LTD.

Effective date: 20141126

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20141126

Address after: Berlin

Applicant after: Shire Orphan Therapies GmbH

Address before: Texas, USA

Applicant before: ALCON RESEARCH, Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210304

Address after: Osaka Japan

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Berlin

Patentee before: Shire Orphan Therapies GmbH

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160323